SOURCE: UCB Pharmaceuticals

July 26, 2005 16:35 ET

Certolizumab Pegol Demonstrates Positive Results in Two Phase III Crohn's Disease Trials

ATLANTA, GA -- (MARKET WIRE) -- July 26, 2005 -- UCB today announced positive results for the two pivotal Phase III trials (PRECISE 1 and 2) of certolizumab pegol (CDP870) in the induction and maintenance of clinical response in moderate to severe active Crohn's disease. The PRECiSE trials assessed the safety and efficacy of CIMZIA™ compared to placebo over a 26-week period, in a total of 1330 patients with active Crohn's disease.

Data from PRECiSE 1 and 2 will be presented in more detail at the major forthcoming gastroenterology medical congresses.

About Crohn's Disease

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract with the disease typically localized in the terminal part of the ileum (a portion of the small intestine) and right colon (a portion of the large intestine). Crohn's disease affects almost 1 million patients worldwide, with the disease typically appearing early in life. Crohn's disease is characterized by a variety of symptoms, although different in every individual, and may include persistent diarrhea, abdominal pain, and at times loss of appetite/weight, fever or rectal bleeding(i). Unfortunately there is no single test to diagnose Crohn's disease and because it can often imitate other gastroenterological conditions, patients may experience a lengthy diagnosis process. Although Crohn's disease affects males and females equally of all ages, the most affected in the U.S. are 20-29 year olds and 30-39 year olds(ii). The disease also occurs in young children and adults over 70 years of age. In addition, American Jews of European backgrounds are more likely than the general population to develop Crohn's disease.

Crohn's Disease - United States (Prevalence)(iii)

Yrs of age       2005            %

0-9             30906            8%
10-19           32491            9
20-29          145598           39%
30-39           68205           18%
40-49           23525            6%
50-59           41850           11%
60-69           11669            3%
70-79           11656            3%
80+              7131            2%

About CIMZIATM

CIMZIATM is a PEGylated Fab' fragment of a humanized anti-TNF alpha monoclonal antibody, with high affinity for both soluble and membrane-bound TNF alpha. CIMZIA™ is also currently the subject of Phase III clinical trials in rheumatoid arthritis.

About UCB

UCB (www.ucb-group.com) is a global biopharmaceutical leader dedicated to the research, development and commercialization of innovative products in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB employs over 8,500 people operating in over 40 countries. UCB is listed on the Euronext Brussels with a market capitalization of approximately EUR 5.8 billion. Worldwide headquarters are located in Brussels, Belgium.

UCB Pharma, Inc. is the North American subsidiary of UCB, with U.S. headquarters located in Smyrna, Georgia. UCB's key products in the U.S. are Keppra® (levetiracetam), Zyrtec®(t) (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex), and Metadate® CD CII (methylphenidate HCl, USP).

(t) Zyrtec is licensed to and co-promoted with Pfizer, Inc. in the United States.

(i) Source: Crohn’s and Colitis Foundation of America; http://ccfa.org/info/about/crohns

(ii) Source: Decision Resources and MattsonJack

(iii) Source: Decision Resources and MattsonJack

Contact Information

  • For inquiries, please contact:
    INVESTOR RELATIONS:
    Jean-Christophe Donck
    Vice President, Corporate Communication & Investor Relations
    Phone +32 2 559 9588
    Email Email Contact

    U.S. MEDIA:
    Lisa Garman
    U.S. Communications/PR
    Phone 770-970-8569
    Email : Email Contact